Acambis PLC Announces Results From Phase 1 Trial Of C. difficile Vaccine
Cambridge, UK and Cambridge, Massachusetts -15 February 2006 - Acambis plc (Acambis) (LSE: ACM, NASDAQ: ACAM) announces results from a Phase 1 trial of its investigational vaccine against Clostridium difficile (C. difficile) in healthy adults.